Related Experiment Videos
High-dose chemotherapy in ovarian carcinoma
1Department of Medicine, University of Mississippi School of Medicine, Jackson, USA.
Seminars in Oncology
|March 12, 1999
Summary
High-dose chemotherapy with autologous transplant shows higher response rates in ovarian cancer but lacks survival data. Randomized trials are needed to confirm benefits over standard chemotherapy.
Area of Science:
- Oncology
- Hematology
Background:
- High-dose chemotherapy with bone marrow transplantation is explored for ovarian carcinoma.
- Previous dose escalation showed increased response rates but no survival advantage.
Purpose of the Study:
- To review attempts at demonstrating advantages of high-dose chemotherapy with autologous transplant in ovarian cancer.
- To assess the current evidence for survival benefits.
Main Methods:
- Review of studies investigating high-dose chemotherapy and autologous transplantation for ovarian carcinoma.
- Analysis of dose escalation data and outcomes.
Main Results:
- Dose escalation without transplant improved response rates but not survival.
- Higher response rates reported with higher chemotherapy doses and autologous transplant.
- Limited survival data available, with potential benefit in specific patient groups.
Conclusions:
- High-dose chemotherapy with autologous transplant remains experimental for ovarian cancer.
- Randomized trials are essential to determine if this approach offers survival advantages over standard chemotherapy.
- Future research should focus on conducting these crucial randomized trials.